Predictive Value of Glucose Transporter-1 and Glucose Transporter-3 for Survival of Cancer Patients: A Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Jan 14

PMID 28086215

Citations 25

Authors

Xiu Chen

Peng Lu

Siying Zhou

Lei Zhang

Jian-Hua Zhao

Jin-Hai Tang

Affiliations

Soon will be listed here.

Abstract

Background And Objective: The role of glucose transporters in cancers remains contradictory. We conducted a systematic review and meta-analysis to assess the association between overall survival and glucose transporter s (GLUTs) 1 and 3 to find an accurate prognostic biomarker.

Methods: We systematically searched the PubMed, EMbase and Medline databases for relevant published studies that were consistent with the eligible criteria up to January 2016, and calculated pooled estimated hazard ratios of GLUT-1 and -3's expressions in different cancer types and ethnic populations. Random-effects models were used to assess estimates from studies with significant heterogeneities.

Results: Overall, 12 studies concerning GLUT 1 and 2 studies concerning GLUT 3, which involved 2008 participants when combined, were included in this analysis. We found that overexpression of GLUTs were significantly correlated to poorer survival rates (HR=1.63, 95%CI=1.09-2.44 and HR=1.89, 95%CI=1.28-2.81). In the subgroup analysis, the GLUT 1 up-regulation was correlated with negative overall survival in pancreatic cancer and gastric cancer and with better overall survival in colorectal cancer. In addition, overexpression of GLUT 1 was associated with a poorer prognosis in the Asian population, while no significance was found in the non-Asian subgroup. However, limitations do exist, which could be handled better.

Conclusions: A combination of GLUTs 1 and 3 might help predict malignancy of cancers and direct effective cancer therapy.

Citing Articles

Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells.

Shen Y, Zhong B, Zheng W, Wang D, Chen L, Song H J Clin Invest. 2024; 134(22).

PMID: 39545407 PMC: 11563678. DOI: 10.1172/JCI178617.

Oxidative stress regulation and related metabolic pathways in epithelial-mesenchymal transition of breast cancer stem cells.

Farahzadi R, Valipour B, Fathi E, Pirmoradi S, Molavi O, Montazersaheb S Stem Cell Res Ther. 2023; 14(1):342.

PMID: 38017510 PMC: 10685711. DOI: 10.1186/s13287-023-03571-6.

An Update on the Metabolic Landscape of Oncogenic Viruses.

Gaballah A, Bartosch B Cancers (Basel). 2022; 14(23).

PMID: 36497226 PMC: 9738352. DOI: 10.3390/cancers14235742.

Metabolic Pathways in Breast Cancer Reprograming: An Insight to Non-Coding RNAs.

Abedi-Gaballu F, Kamal Kazemi E, Salehzadeh S, Mansoori B, Eslami F, Emami A Cells. 2022; 11(19).

PMID: 36230935 PMC: 9563138. DOI: 10.3390/cells11192973.

MicroRNAs-mediated regulation of glucose transporter (GLUT) expression in glioblastoma.

Beylerli O, Sufianova G, Shumadalova A, Zhang D, Gareev I Noncoding RNA Res. 2022; 7(4):205-211.

PMID: 36157351 PMC: 9467858. DOI: 10.1016/j.ncrna.2022.09.001.

References

Ramani P, Headford A, May M . GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Virchows Arch. 2013; 462(2):203-9. DOI: 10.1007/s00428-012-1370-4. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Chan D, Sutphin P, Nguyen P, Turcotte S, Lai E, Banh A . Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011; 3(94):94ra70. PMC: 3683134. DOI: 10.1126/scitranslmed.3002394. View

Kallinowski F, Schlenger K, Runkel S, Kloes M, Stohrer M, Okunieff P . Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res. 1989; 49(14):3759-64. View

Lastraioli E, Bencini L, Bianchini E, Romoli M, Crociani O, Giommoni E . hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. Transl Oncol. 2012; 5(2):105-12. PMC: 3323932. DOI: 10.1593/tlo.11250. View

Furudoi A, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G . Clinical significance of human erythrocyte glucose transporter 1 expression at the deepest invasive site of advanced colorectal carcinoma. Oncology. 2001; 60(2):162-9. DOI: 10.1159/000055314. View

Kawamura T, Kusakabe T, Sugino T, Watanabe K, Fukuda T, Nashimoto A . Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer. 2001; 92(3):634-41. DOI: 10.1002/1097-0142(20010801)92:3<634::aid-cncr1364>3.0.co;2-x. View

Cleven A, van Engeland M, Wouters B, de Bruine A . Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol. 2007; 29(3):229-40. PMC: 4617795. DOI: 10.1155/2007/945802. View

Huang X, Chen X, Xie X, Zhou Q, Li K, Li S . Co-expression of CD147 and GLUT-1 indicates radiation resistance and poor prognosis in cervical squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7(4):1651-66. PMC: 4014246. View

10.

Schlosser H, Drebber U, Urbanski A, Haase S, Baltin C, Berlth F . Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival. Gastric Cancer. 2015; 20(1):83-91. DOI: 10.1007/s10120-015-0577-x. View

11.

Alakus H, Batur M, Schmidt M, Drebber U, Baldus S, Vallbohmer D . Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun. 2010; 31(6):532-8. DOI: 10.1097/MNM.0b013e32833823ac. View

12.

Mueckler M, Thorens B . The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013; 34(2-3):121-38. PMC: 4104978. DOI: 10.1016/j.mam.2012.07.001. View

13.

Kobayashi M, Kaida H, Kawahara A, Hattori S, Kurata S, Hayakawa M . The relationship between GLUT-1 and vascular endothelial growth factor expression and 18F-FDG uptake in esophageal squamous cell cancer patients. Clin Nucl Med. 2012; 37(5):447-52. DOI: 10.1097/RLU.0b013e31823924bb. View

14.

Pizzi S, Porzionato A, Pasquali C, Guidolin D, Sperti C, Fogar P . Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol. 2008; 24(2):175-85. DOI: 10.14670/HH-24.175. View

15.

Nie Y, Liu Y, Luo Q, Huang S . Effect of dexmedetomidine combined with sufentanil for post-caesarean section intravenous analgesia: a randomised, placebo-controlled study. Eur J Anaesthesiol. 2014; 31(4):197-203. DOI: 10.1097/EJA.0000000000000011. View

16.

Mori Y, Tsukinoki K, Yasuda M, Miyazawa M, Kaneko A, Watanabe Y . Glucose transporter type 1 expression are associated with poor prognosis in patients with salivary gland tumors. Oral Oncol. 2006; 43(6):563-9. DOI: 10.1016/j.oraloncology.2006.06.006. View

17.

Yu M, Zhou Q, Zhou Y, Fu Z, Tan L, Ye X . Metabolic phenotypes in pancreatic cancer. PLoS One. 2015; 10(2):e0115153. PMC: 4342019. DOI: 10.1371/journal.pone.0115153. View

18.

Sadlecki P, Bodnar M, Grabiec M, Marszalek A, Walentowicz P, Sokup A . The role of Hypoxia-inducible factor-1 α , glucose transporter-1, (GLUT-1) and carbon anhydrase IX in endometrial cancer patients. Biomed Res Int. 2014; 2014:616850. PMC: 3972900. DOI: 10.1155/2014/616850. View

19.

Bjerregaard J, Mortensen M, Pfeiffer P . Trends in cancer of the liver, gall bladder, bile duct, and pancreas in elderly in Denmark, 1980-2012. Acta Oncol. 2016; 55 Suppl 1:40-5. DOI: 10.3109/0284186X.2015.1114675. View

20.

Hommell-Fontaine J, Isaac S, Passot G, Decullier E, Traverse-Glehen A, Cotte E . Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol. 2013; 20(12):3892-8. DOI: 10.1245/s10434-013-3077-4. View